DE102016123859B3 - Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie - Google Patents

Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie Download PDF

Info

Publication number
DE102016123859B3
DE102016123859B3 DE102016123859.7A DE102016123859A DE102016123859B3 DE 102016123859 B3 DE102016123859 B3 DE 102016123859B3 DE 102016123859 A DE102016123859 A DE 102016123859A DE 102016123859 B3 DE102016123859 B3 DE 102016123859B3
Authority
DE
Germany
Prior art keywords
tcr
antigen
cancer
seq
chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE102016123859.7A
Other languages
German (de)
English (en)
Inventor
Leonie ALTEN
Sebastian Bunk
Dominik Maurer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Immatics Biotechnologies GmbH
Original Assignee
Immatics Biotechnologies GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to DE102016123859.7A priority Critical patent/DE102016123859B3/de
Application filed by Immatics Biotechnologies GmbH filed Critical Immatics Biotechnologies GmbH
Priority to NZ754366A priority patent/NZ754366A/en
Priority to KR1020197019008A priority patent/KR20190086562A/ko
Priority to MX2019006727A priority patent/MX2019006727A/es
Priority to AU2017373815A priority patent/AU2017373815C1/en
Priority to CR20190276A priority patent/CR20190276A/es
Priority to CN201780075298.4A priority patent/CN110036027A/zh
Priority to EP17825768.9A priority patent/EP3551654A1/en
Priority to BR112019010699-5A priority patent/BR112019010699A2/pt
Priority to JP2019528908A priority patent/JP2020511936A/ja
Priority to CA3045234A priority patent/CA3045234A1/en
Priority to US15/835,095 priority patent/US10527623B2/en
Priority to PE2019001096A priority patent/PE20191081A1/es
Priority to MYPI2019003103A priority patent/MY196025A/en
Priority to PCT/EP2017/081893 priority patent/WO2018104478A1/en
Priority to TW106143135A priority patent/TW201828977A/zh
Publication of DE102016123859B3 publication Critical patent/DE102016123859B3/de
Application granted granted Critical
Priority to US16/025,434 priority patent/US10725044B2/en
Priority to CL2019001537A priority patent/CL2019001537A1/es
Priority to IL267131A priority patent/IL267131A/en
Priority to PH12019501263A priority patent/PH12019501263A1/en
Priority to CONC2019/0006926A priority patent/CO2019006926A2/es
Priority to US16/828,577 priority patent/US20200249233A1/en
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
DE102016123859.7A 2016-12-08 2016-12-08 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie Expired - Fee Related DE102016123859B3 (de)

Priority Applications (22)

Application Number Priority Date Filing Date Title
DE102016123859.7A DE102016123859B3 (de) 2016-12-08 2016-12-08 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
MYPI2019003103A MY196025A (en) 2016-12-08 2017-12-07 Novel T Cell Receptors and Immune Therapy Using the Same
MX2019006727A MX2019006727A (es) 2016-12-08 2017-12-07 Nuevos receptores de celulas t y terapia inmunologica que los utiliza.
AU2017373815A AU2017373815C1 (en) 2016-12-08 2017-12-07 Novel T cell receptors and immune therapy using the same
CR20190276A CR20190276A (es) 2016-12-08 2017-12-07 Nuevos receptores de células t y terapia inmunológica que los utiliza
CN201780075298.4A CN110036027A (zh) 2016-12-08 2017-12-07 新型t细胞受体及其免疫治疗应用
EP17825768.9A EP3551654A1 (en) 2016-12-08 2017-12-07 Novel t cell receptors and immune therapy using the same
BR112019010699-5A BR112019010699A2 (pt) 2016-12-08 2017-12-07 receptores de células t e imunoterapia empregando os mesmos
JP2019528908A JP2020511936A (ja) 2016-12-08 2017-12-07 新規ｔ細胞受容体およびそれを用いた免疫療法
KR1020197019008A KR20190086562A (ko) 2016-12-08 2017-12-07 T 세포 수용체 및 이를 사용하는 면역 요법
NZ754366A NZ754366A (en) 2016-12-08 2017-12-07 Novel t cell receptors and immune therapy using the same
PE2019001096A PE20191081A1 (es) 2016-12-08 2017-12-07 Nuevos receptores de celulas t y terapia inmunologica que los utiliza
PCT/EP2017/081893 WO2018104478A1 (en) 2016-12-08 2017-12-07 Novel t cell receptors and immune therapy using the same
CA3045234A CA3045234A1 (en) 2016-12-08 2017-12-07 Novel t cell receptors and immune therapy using the same
US15/835,095 US10527623B2 (en) 2016-12-08 2017-12-07 T cell receptors and immune therapy using the same
TW106143135A TW201828977A (zh) 2016-12-08 2017-12-08 新穎t細胞受體以及使用彼之免疫療法
US16/025,434 US10725044B2 (en) 2016-12-08 2018-07-02 T cell receptors and immune therapy using the same
CL2019001537A CL2019001537A1 (es) 2016-12-08 2019-06-05 Nuevos receptores de células t y terapia inmunológica que los utiliza.
IL267131A IL267131A (en) 2016-12-08 2019-06-05 Novel t cell receptors and immune therapy using the same
PH12019501263A PH12019501263A1 (en) 2016-12-08 2019-06-06 Novel t cell receptors and immune therapy using the same
CONC2019/0006926A CO2019006926A2 (es) 2016-12-08 2019-06-27 Nuevos receptores de células t y terapia inmunológica que los utiliza
US16/828,577 US20200249233A1 (en) 2016-12-08 2020-03-24 Novel t cell receptors and immune therapy using the same

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE102016123859.7A DE102016123859B3 (de) 2016-12-08 2016-12-08 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie

Publications (1)

Publication Number Publication Date
DE102016123859B3 true DE102016123859B3 (de) 2018-03-01

Family

ID=61167304

Family Applications (1)

Application Number Title Priority Date Filing Date
DE102016123859.7A Expired - Fee Related DE102016123859B3 (de) 2016-12-08 2016-12-08 Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie

Country Status (14)

Country Link
US (3) US10527623B2 (enExample)
EP (1) EP3551654A1 (enExample)
JP (1) JP2020511936A (enExample)
KR (1) KR20190086562A (enExample)
CN (1) CN110036027A (enExample)
AU (1) AU2017373815C1 (enExample)
BR (1) BR112019010699A2 (enExample)
CA (1) CA3045234A1 (enExample)
CR (1) CR20190276A (enExample)
DE (1) DE102016123859B3 (enExample)
MX (1) MX2019006727A (enExample)
PE (1) PE20191081A1 (enExample)
TW (1) TW201828977A (enExample)
WO (1) WO2018104478A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521776A (ja) * 2018-04-19 2021-08-30 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System Ｍａｇｅ−ｂ２特異性を有するｔ細胞受容体およびその使用

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102016123893A1 (de) 2016-12-08 2018-06-14 Immatics Biotechnologies Gmbh T-Zellrezeptoren mit verbesserter Bindung
KR20200119840A (ko) 2018-02-09 2020-10-20 이매틱스 유에스 인코포레이티드 T 세포의 제조 방법
DE102018108612A1 (de) 2018-03-21 2019-09-26 Immatics US, Inc. Verfahren zur erhöhung der persistenz von adoptiv infundierten t-zellen
US20200297768A1 (en) 2019-03-19 2020-09-24 Immatics US, Inc. Cd28 t cell cultures, compositions, and methods of using thereof
DE102019108125B4 (de) 2019-03-28 2022-02-03 Immatics US, Inc. Cd28 t-zellkulturen, zusammensetzungen und verfahren zu deren verwendung
KR20220029584A (ko) 2019-05-27 2022-03-08 이매틱스 유에스 인코포레이티드 바이러스 벡터 및 입양 세포 요법에서 그 사용
AU2020286756A1 (en) 2019-06-06 2022-01-27 Immatics Biotechnologies Gmbh Sorting with counter selection using sequence similar peptides
US20220251235A1 (en) * 2019-07-09 2022-08-11 Medigene Immunotherapies Gmbh Magea10 specific t cell receptors and their use
AU2020319880B2 (en) * 2019-08-01 2026-08-13 The University Of North Carolina At Chapel Hill Compositions and methods for binding antibodies and inhibiting neutralizing antibodies
US20210032370A1 (en) 2019-08-02 2021-02-04 Immatics Biotechnologies Gmbh Recruiting agent further binding an mhc molecule
WO2021086991A1 (en) * 2019-10-30 2021-05-06 The Regents Of The University Of California Methods of treating systemic lupus erythematosus
CN114929733A (zh) * 2019-11-08 2022-08-19 古德T细胞有限公司 调节性t细胞表面抗原的表位和与其特异性结合的抗体
JP2023515131A (ja) 2020-02-24 2023-04-12 イマティクス ユーエス，アイエヌシー． がんおよび関連する悪性腫瘍の治療のためにｔ細胞を増殖させる方法
DE102020111571A1 (de) 2020-03-11 2021-09-16 Immatics US, Inc. Wpre-mutantenkonstrukte, zusammensetzungen und zugehörige verfahren
CN113621070A (zh) * 2020-05-06 2021-11-09 华夏英泰（北京）生物技术有限公司 一种t细胞抗原受体、其多聚体复合物及其制备方法和应用
CN111574616B (zh) * 2020-06-17 2021-02-02 深圳豪石生物科技有限公司 分离的t细胞受体和应用
CN111624342A (zh) * 2020-07-11 2020-09-04 成都益安博生物技术有限公司 一种卵巢癌的外周血tcr标志物及其检测试剂盒和应用
WO2022040631A1 (en) 2020-08-21 2022-02-24 Immatics US, Inc. Methods for isolating cd8+ selected t cells
CR20230295A (es) 2020-12-31 2023-07-27 Immatics Us Inc Polipéptidos cd8, composiciones y métodos de uso de estos
DE102021100038A1 (de) 2020-12-31 2022-06-30 Immatics US, Inc. Modifizierte cd8-polypeptide, zusammensetzungen und verfahren zu deren verwendung
KR20240004937A (ko) 2021-05-05 2024-01-11 이매틱스 바이오테크놀로지스 게엠베하 Bma031 항원 결합 폴리펩타이드
EP4392441A1 (en) 2021-08-24 2024-07-03 Immatics US, Inc. Selection of immune cells using peptide mhc complexes generated by conditional ligand exchange
US20230089392A1 (en) 2021-09-20 2023-03-23 Immatics US, Inc. Monocyte depletion of t cells populations for t-cell therapy
CN118541392A (zh) 2021-09-28 2024-08-23 准星生物医药有限公司 多种形式的分子复合物
WO2023081925A1 (en) 2021-11-08 2023-05-11 Immatics Biotechnologies Gmbh Adoptive cell therapy combination treatment and compositions thereof
US20230142468A1 (en) 2021-11-08 2023-05-11 Immatics US, Inc. Methods for generating cell spheroids
CA3243030A1 (en) * 2021-12-21 2025-02-26 Amgen Inc. Dcaf4l2-specific t-cell receptors
WO2023212655A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Il-12 polypeptides, il-15 polypeptides, il-18 polypeptides, cd8 polypeptides, compositions, and methods of using thereof
US20230348561A1 (en) 2022-04-28 2023-11-02 Immatics US, Inc. Dominant negative tgfbeta receptor polypeptides, cd8 polypeptides, cells, compositions, and methods of using thereof
KR20250018168A (ko) 2022-04-28 2025-02-04 이매틱스 유에스 인코포레이티드 막-결합된 il-15, cd8 폴리펩티드, 세포, 조성물, 및 이의 사용 방법
EP4519418A1 (en) 2022-05-05 2025-03-12 Immatics US, Inc. Methods for improving t cell efficacy
JP2024012879A (ja) * 2022-07-19 2024-01-31 国立大学法人三重大学 腫瘍反応性ｔ細胞の製造方法
CN115216514B (zh) * 2022-08-01 2026-03-17 中国科学技术大学 Vam6（Vps39）作为靶点在药物筛选、基因编辑以及疾病治疗中的应用
WO2024139780A1 (zh) * 2022-12-26 2024-07-04 上海市第一人民医院 靶向巨细胞病毒pp65的T细胞受体和表达其的T细胞及应用
EP4750486A2 (en) * 2023-07-25 2026-06-03 Memorial Sloan Kettering Cancer Center T cell receptors targeting tp53 hotspot mutations and uses thereof
US20250134931A1 (en) 2023-11-01 2025-05-01 Immatics US, Inc. Membrane-bound il-15, cd8 polypeptides, cells, compositions, and methods of using thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011210A2 (en) * 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5714352A (en) 1996-03-20 1998-02-03 Xenotech Incorporated Directed switch-mediated DNA recombination
WO2001058479A1 (en) 2000-02-08 2001-08-16 The Penn State Research Foundation Immunotherapy using interleukin 13 receptor subunit alpha 2
EP2660250B1 (en) * 2012-05-02 2018-11-14 Deutsches Rheuma-Forschungszentrum Berlin Tcr transgenic mouse model for immune disease
US9879065B2 (en) * 2012-09-14 2018-01-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing MHC class II-restricted MAGE-A3
EP3572510B1 (en) 2013-11-21 2022-09-21 Repertoire Genesis Incorporation T cell receptor and b cell receptor repertoire analysis system, and use of same in treatment and diagnosis
CN105506065A (zh) * 2014-09-25 2016-04-20 上海人类基因组研究中心 肝癌基因检测方法、检测试剂盒及其应用
GB201505305D0 (en) * 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
GB201520583D0 (en) * 2015-11-23 2016-01-06 Immunocore Ltd & Adaptimmune Ltd Peptides

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016011210A2 (en) * 2014-07-15 2016-01-21 Juno Therapeutics, Inc. Engineered cells for adoptive cell therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
WANG, H. [u.a.]: DCAF4L2 promotes colorectal cancer invasion and metastasis via mediating degradation of NFκb negative regulator PPM1B. Am. J. Transl. Res. (elektronisch veröffentlicht am 15.02.2016) 8 (2) 405-18 *

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2021521776A (ja) * 2018-04-19 2021-08-30 ボード オブ リージェンツ, ザ ユニバーシティ オブ テキサス システムBoard Of Regents, The University Of Texas System Ｍａｇｅ−ｂ２特異性を有するｔ細胞受容体およびその使用
JP7469807B2 (ja) 2018-04-19 2024-04-17 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用
JP2024074861A (ja) * 2018-04-19 2024-05-31 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用
US12202877B2 (en) 2018-04-19 2025-01-21 Board Of Regents, The University Of Texas System T cell receptors with mage-B2 specificity and uses thereof
JP7761293B2 (ja) 2018-04-19 2025-10-28 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Ｍａｇｅ－ｂ２特異性を有するｔ細胞受容体およびその使用

Also Published As

Publication number Publication date
AU2017373815A1 (en) 2019-06-27
KR20190086562A (ko) 2019-07-22
MX2019006727A (es) 2019-09-09
CA3045234A1 (en) 2018-06-14
CN110036027A (zh) 2019-07-19
US10725044B2 (en) 2020-07-28
TW201828977A (zh) 2018-08-16
PE20191081A1 (es) 2019-08-20
JP2020511936A (ja) 2020-04-23
BR112019010699A2 (pt) 2019-10-22
WO2018104478A1 (en) 2018-06-14
US20180306789A1 (en) 2018-10-25
AU2017373815C1 (en) 2021-08-26
US20200249233A1 (en) 2020-08-06
AU2017373815B2 (en) 2020-12-10
CR20190276A (es) 2019-10-30
US20180164315A1 (en) 2018-06-14
EP3551654A1 (en) 2019-10-16
US10527623B2 (en) 2020-01-07

Similar Documents

Publication Publication Date Title
DE102016123847B3 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
DE102016115246B3 (de) Neue t-zellrezeptoren und deren verwendung in immuntherapie
US20240285779A1 (en) Novel t cell receptors and immune therapy using the same
DE102017106305A1 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapien gegen prame-positive Krebsarten
DE102017114737A1 (de) Neue T-Zellrezeptoren und deren Verwendung in Immuntherapie
US20220098270A1 (en) T cell receptors and immune therapy using the same against prame positive cancers
US10725044B2 (en) T cell receptors and immune therapy using the same
DE102017125888A1 (de) Neue konstruierte T-Zell-Rezeptoren und deren Verwendung in Immuntherapie
HK40078003A (en) Novel t cell receptors and immune therapy using the same
HK40117524A (en) T cell receptors and immune therapy using the same against prame positive cancers
HK40014640B (en) Novel t cell receptors and immune therapy using the same
HK40014640A (en) Novel t cell receptors and immune therapy using the same
HK40020731B (en) T cell receptors and immune therapy using the same against prame positive cancers
HK40020731A (en) T cell receptors and immune therapy using the same against prame positive cancers

Legal Events

Date Code Title Description
R012 Request for examination validly filed
R163 Identified publications notified
R016 Response to examination communication
R018 Grant decision by examination section/examining division
R020 Patent grant now final
R082 Change of representative

Representative=s name: ZSP PATENTANWAELTE PARTG MBB, DE

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

R082 Change of representative

Representative=s name: ZWICKER SCHNAPPAUF & PARTNER PATENTANWAELTE PA, DE

R119 Application deemed withdrawn, or ip right lapsed, due to non-payment of renewal fee